Zevra Therapeutics (ZVRA) EBT Margin (2019 - 2026)
Zevra Therapeutics (ZVRA) posted EBT Margin of 123.7% for Q1 2026, up 233.71% on a QoQ basis from 37.07% in Q4 2025, and up 13310.0% year-over-year from N/an in Q1 2025.
Zevra Therapeutics (ZVRA) EBT Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics' EBT Margin history runs 8 years deep, the most recent figure standing at 123.7% for Q1 2026.
- Quarterly EBT Margin rose 13310.0% year-over-year to 123.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 109.04% (up 29510.0% YoY) and the FY2025 annual result came in at 81.41%, up 46317.0% from the prior year.
- EBT Margin was 123.7% for Q1 2026 at Zevra Therapeutics, up from 37.07% in the prior quarter.
- Across five years, EBT Margin topped out at 297.15% in Q2 2025 and bottomed at 1751.76% in Q2 2022.
- A 5-year average of 289.18% and a median of 161.76% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin tumbled 180351 bps — and 2023, when it jumped 172051 bps.
- Zevra Therapeutics' EBT Margin stood at 148.66% in 2022, then dropped by 4 bps to 153.96% in 2023, then slipped by 10 bps to 169.56% in 2024, then surged by 122 bps to 37.07% in 2025, then soared by 234 bps to 123.7% in 2026.
- Business Quant data shows ZVRA's EBT Margin at 123.7% in Q1 2026, 37.07% in Q4 2025, and 3.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 123.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123.70% |
| Dec 31, 2025 | 37.07% |
| Sep 30, 2025 | -3.75% |
| Jun 30, 2025 | 297.15% |
| Mar 31, 2025 | -9.40% |
| Dec 31, 2024 | -169.56% |
| Sep 30, 2024 | -899.19% |
| Jun 30, 2024 | -451.25% |
| Mar 31, 2024 | -487.36% |
| Dec 31, 2023 | -153.96% |
| Sep 30, 2023 | -351.99% |
| Jun 30, 2023 | -31.25% |
| Mar 31, 2023 | -419.40% |
| Dec 31, 2022 | -148.66% |
| Sep 30, 2022 | -207.20% |
| Jun 30, 2022 | -1,751.76% |
| Dec 31, 2021 | -103.37% |
| Sep 30, 2021 | -89.52% |
| Jun 30, 2021 | 51.75% |
| Mar 31, 2021 | -84.97% |